Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

Cancer Cell
16 January 2021
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00051-9

Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

Submitted by baileylynn_100964 on Fri, 02/12/2021 - 06:49
Date
Trial Icon

The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice

Gynecol Oncol
30 April 2011
https://pubmed.ncbi.nlm.nih.gov/21531450/

Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment

Invest New Drugs
August 2013
https://pubmed.ncbi.nlm.nih.gov/23275062/

Metabolic treatment of cancer: intermediate results of a prospective case series

Anticancer Res
February 2014
https://pubmed.ncbi.nlm.nih.gov/24511042/

Background: The combination of hydroxycitrate and lipoic acid has been demonstrated by several laboratories to be effective in reducing murine cancer growth.

Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3--a case report

Oral Health Dent Manag
September 2014
http://oralhealth.ro/volumes/2014/volume-3/Paper662.pdf

Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases

Integr Cancer Ther
December 2009
https://pubmed.ncbi.nlm.nih.gov/20042414/

Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone

Cancer Lett
29 March 1996
https://pubmed.ncbi.nlm.nih.gov/8620464/